基于生物信息学方法筛选卵巢癌铂类化疗耐药相关基因的研究  

Bioinformatics Analysis of Related Genes in Platinum-resistant Ovarian Cancer

作　　者：韦仕洋[1] 张明铭[2] 黄晶[2] 林丽娜[1] 徐红[1] 

机构地区：[1]广西医科大学第一附属医院妇科,南宁市530021 [2]广西壮族自治区妇幼保健院,南宁市530003

出　　处：《广西医学》2014年第12期1692-1694,共3页Guangxi Medical Journal

摘　　要：目的从分子水平揭示卵巢癌化疗耐药的发病机制,为进一步的临床研究提供参考。方法在公共基因芯片数据库GEO中找到卵巢癌相关基因芯片数据,使用Bioconductor R 2.13.0软件包对其进行分析,找到卵巢癌化疗铂类化疗耐药相关基因;利用STRING 9.1、DAVID 6.7在线工具对这些基因进行生物学分析。结果共获得283个差异表达基因,其中表达上调基因69个,下调表达基因214个。62个基因的蛋白有相互关系,确定ESR1、IGF1、SDC2、ADCY2、ADCY8、PTHLH、BMP等为关键基因。这些基因的功能主要涉及底物特异性通道活性、被动的跨膜转运活性,参与钙信号通路、MAPK信号通路等。结论利用生物信息学的方法分析基因芯片数据可有效筛选并确定其中的关键基因,卵巢癌铂类化疗耐药的发生与基因分子水平表达变化有关,确定复发性卵巢癌相关基因的功能及其参与通路为研究卵巢癌耐药的治疗靶点提供了新的思路。Objective To investigate the molecular pathogenesis in platinum-resistant ovarian cancer for further study. Methods The gene chip data were retrieval microarray ovarian cancer in Gene Expression Omnibus database and analyzed by Bioconductor R 2. 13. 0,and the related genes in platinum-resistant ovarian cancer were screened out. The genes were analyzed with on-line bioinformatics tools STRING 9. 1 and DAVID 6. 7. Results A total of 283 differentially expressed genes were screened out,with 69 up-regulated genes and 214 down-regulated genes. 62 proteins / genes existed interaction between each other. ESR1,IGF1,SDC2,ADCY2,ADCY8,PTHLH and BMP were identified as key genes in the pathogenesis of platinum-resistant ovarian cancer. The main biological processes might involve in substrate-specific channel activity,passive transmembrane transport activity,calcium signaling pathway and MAPK signaling pathway.Conclusion Bioinformatics methods can be adopted to screen out gene chip data effectively and then identify key genes. The occurrence and development of chemo-resistant ovarian cancer involves in changes in molecular level,and the investigations on these genes＇ function and their signaling pathway may provide valuable data and theory basis into the molecular mechanisms for the treatment of chemo-resistant ovarian cancer.

关 键 词：卵巢癌 化学治疗 耐药 基因 生物信息学 

分 类 号：R737.31[医药卫生—肿瘤]